Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRK 001

Next Previous
Search
Drug Profile

TRK 001

Alternative Names: Autologous T regulatory cell therapy - TRACT Therapeutics; TRK-001

Latest Information Update: 27 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tract Therapeutics
  • Developer Northwestern University; Tract Therapeutics
  • Class T lymphocyte cell therapies
  • Mechanism of Action Regulatory T-lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity No

Highest Development Phases

  • Phase I Renal transplant rejection
  • Preclinical Crohn's disease
  • Discontinued Autoimmune hepatitis; Liver transplant rejection

Most Recent Events

  • 13 Aug 2024 Tract Therapeutics plans a phase II RETIRE trial for Renal transplant rejection (Prevention) in the US, Taiwan (IV, Infusion) in December 2024 (NCT06552169)
  • 21 Sep 2023 Phase I development is ongoing in Renal transplant rejection (Prevention) in USA (IV) (Tract Therapeutics pipeline, September 2023)
  • 21 Sep 2023 Preclinical development is ongoing in Crohn's disease in USA (IV) (Tract Therapeutics pipeline, September 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top